The agreement extends the customer's suite of cloud DevOps, data engineering, and data platform management solutions
Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
The newly launched Genomic Health Insights (GHI) program to make sequencing accessible to all
The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Advances clinical research capabilities with leading regulatory grade registries platform
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Subscribe To Our Newsletter & Stay Updated
